Key points are not available for this paper at this time.
Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Wanner et al. (Wed,) studied this question.